Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Thumbnail

Lower blood pressure, BMI may precede dementia

Low blood pressure (BP) and weight loss could signal an impending diagnosis of dementia, while elevated blood glucose levels may represent a consistent risk factor for the condition, according to a 14-year study published in the October issue of JAMA Psychiatry.

Thumbnail

AHA, CHF funnel $776K into congenital heart defect research

The American Heart Association and Children’s Heart Foundation are dedicating $776,000 to four upcoming research projects focused on congenital heart defects (CHDs), the AHA announced in late October.

Thumbnail

NHS England: 500 diabetics die each week from preventable complications

Figures released by England’s National Health Service have revealed that around 500 U.K. residents die prematurely each week from complications of diabetes, including amputations, CVD, stroke and kidney disease.

Canagliflozin becomes first oral diabetes drug approved to reduce MACE

The FDA has approved canagliflozin (Invokana) to reduce the risk of major adverse cardiovascular events (MACE) including stroke, heart attack and cardiac death in patients with type 2 diabetes and established cardiovascular disease. It is the first oral diabetes medication to gain this indication, according to drug manufacturer Janssen Pharmaceutical Companies.

Beta-blockers, RASBs reduce mortality in HF patients with midrange EF

Guideline-directed medical therapies like beta-blockers and renin-angiotensin system blockers (RASBs)—but not aldosterone antagonists—are associated with improved outcomes in heart failure patients hospitalized with a midrange ejection fraction, researchers reported in the current edition of the Journal of the American Heart Association.

NIH pauses $63M stem cell trial for heart failure amid controversy

The National Institutes of Health (NIH) is pausing a taxpayer-funded, $63 million trial of cardiac stems cells over questions about the basis for the research.

Thumbnail

Most cases of SCAD can’t be traced back to apparent risk factors

Though it’s been linked tenuously in the past to psychological stressors and genetics, the majority of cases of spontaneous coronary artery dissection (SCAD) can’t be traced back to a concomitant arteriopathy, inflammatory disorder or evident risk factor, according to research published in the American Journal of Cardiology Oct. 29.

Thumbnail

Wider thrombectomy window chosen as No. 3 medical innovation for 2019

The expanded window for thrombectomy in acute stroke care ranked No. 3 on Cleveland Clinic’s top 10 medical innovations for 2019—one of several developments on the list with implications for cardiovascular treatment.